StockNews.AISignal intelligence
Progyny, Inc. · NASDAQ · Healthcare
Browse public PGNY signals with their source context and measured market impact. Open any signal for its permanent analysis page.
Progyny leads fertility benefits with outcomes-based employer solutions. Stock up ~90% last year; market prices strong future growth. LTM revenue growth 11.4% and free cash flow margin 15.25%. Operating margin 6.8% lags device peers; P/E 40.8 implies high valuation.
View signal analysisProgyny's Q3 earnings missed analysts' estimates significantly. Company's revenue guidance for FY24 is below analyst expectations. Utilization rate patterns led to lower treatment consumption. Analysts downgraded Progyny's stock rating post-earnings announcement. Progyny shares fell 15.1%, reflecting investor disappointment.
View signal analysis